Neuroendocrine tumours of the gastrointestinal tract;Neuroendokrine tumoren des gastrointestinaltrakts

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 6, 2004, Pages 517-526

  Plöckinger, Ursula ^a   Wiedenmann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biotherapy; Carcinoid syndrome; Chemotherapy; Gastrinoma; Gastrointestinal neuroendocrine tumours; Insulinoma; Non functioning neuroendocrine tumour

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHENODEOXYCHOLIC ACID; CHROMOGRANIN A; CHROMOGRANIN B; CISPLATIN; DIAZOXIDE; DOXORUBICIN; FLUOROURACIL; GASTRIN; GLUCAGON; INSULIN; LANSOPRAZOLE; NEURON SPECIFIC ENOLASE; NEUROTENSIN; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RECOMBINANT ALPHA2B INTERFERON; SECRETIN; SEROTONIN; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SYNAPTOPHYSIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALGORITHM; ARTIFICIAL EMBOLISM; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC IMAGING; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; GASTROINTESTINAL TRACT SCINTISCANNING; GASTROINTESTINAL TUMOR; GLUCAGONOMA; HUMAN; HYPERTHERMIC THERAPY; INSULINOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PEROPERATIVE ECHOGRAPHY; PROGNOSIS; REVIEW; SOMATOSTATINOMA; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; URINALYSIS; VIPOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PALLIATIVE CARE; PATIENT CARE MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; TREATMENT OUTCOME;

EID: 3042786567     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812697     Document Type: Review

References (38)

1. Modlin IN, Sandor A. An Analysis of 8305 Cases of Carcinoid Tumors. Cancer 1997; 79: 813-829
2. Moertel CG. An Odyssey in the Land of Small Tumors. J Clin Oncology 1987; 5: 1503-1522
3. Perry RR, Vinik AI. Clinical review: Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80: 2273-2278
4. Smith SL, Branton SA, Avino AJ et al. Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature. Surgery 1998; 124: 1050
5. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996; 71: 1030-1038
6. Smith AP, Doolas A, Staren ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol 1996; 61: 306-309
7. Angeletti S, Corleto VD, Schillaci O et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42: 792-794
8. Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumours. Surg Clin North Am 1987; 67: 379-393
9. Zimmer T, Scherubl H, Faiss S et al. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000; 62 (Suppl 1): 45-50
10. Jensen RT. Zollinger-Ellison Syndrom. In: Doherty GM, Skögseid B (ed). Surgical Endocrinology. Philadelphia: Lippincott Willliams & Wilkins, 2001; 291-344
11. Li ML, Norton JA. Gastrinoma. Current Treatment Options Oncol 2001; 2: 337-346
12. Goldfinger SE. Management and prognosis of the Zollinger-Ellison Syndrome (Gastrinoma). In: UpToDate, Rose BD (eds). Wellesley, MA 2003: 461-478
13. Lehnert H, Becker W, Dralle H et al. Neuroendokrine Tumore des Gastrointestinaltrakts. In: Lehnert H (Hrsg). Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. 2. Auflage. Stuttgart: Georg Thieme Verlag, 2003
14. Jaeck D, Oussoultzogiou E, Bachellier P et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001; 25: 689-692
15. McEntee GP, Nagorney DM, Kvols LK et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091
16. Pape UF, Böhmig M, Berndt U et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci 2004; 1014: 222-233
17. Evans DB, Skibber JM, Lee JE et al. Nonfunctioning islet cell carcinoma of the pancreas, Surgery 1993; 114: 1175-1182
18. Wiedenmann B, Plöckinger U. Neuroendocrine gastroenteropancreatic tumors. In: Peckham M, Pinedo H, Veronesi U (eds). Oxford Textbook of Oncology. Endocrine Tumours. Oxford/New York/Tokyo: Oxford University Press, 1999; 19: 2819-2833
19. Pellikka PA, Tajik AJ, Khandheria BK et al. Carcinoid Heart Disease: Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87: 1188-1196
20. Dingerkus H, Voller H, Schröder K et al. Endokardfibrose bei neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Dtsch Med Wochenschr 1994: 119: 647-652
21. Plöckinger U, Wiedenmann B. Systemic Therapy for Metastatic or Residual Extrapancreatic Neuroendocrine Tumors. In: Doherty GM, Skögseid B (eds). Surgical Endocrinology. Philadelphia: Lippincott Willliams & Wilkins, 2001; 461-478
22. O'Toole D, Ducreux M, Bommelaer G et al. Treatment of carcinoid syndrome. A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88: 770-776
23. Aparicio T, Bucreux M, Baudin E et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019
24. Faiss S, Pape UF, Böhmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lancreotide, interferon-alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon-alfa Study Group. J Clin Oncol 2003; 21: 2689-2696
25. Hejna M, Schmidinger M, Raderer M. The clinical tole role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13: 653-668
26. Quabbe HJ, Plöckinger U. Treatment of acromegaly with long-acting somatostatin analogues. In: von Werder K, Fahlbusch R (eds). Pituitary adenomas. From basic research to diagnosis and therapy. Lausanne: Elsevier Science, 1996; 31-41
27. Plöckinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990; 71: 1658-1662
28. Detjen KM, Kehrberger JP, Drost A et al. Interferon-α inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol 2002; 21: 1133-1140
29. Öberg K. Interferon in the management of neuroendocrine GEP tumors. Digestion 2000; 62 (suppl 1): 92-97
30. Öberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer drugs 1994; 5: 503-519
31. Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519
32. Ritzel U, Leonhardt U, Stockmann F et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 1995; 90: 627-631
33. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposid and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232
34. Mitry E, Baudin E, Ducreaux M et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 2000; 81: 1351-1355
35. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. QJ Int Med 2000; 44: 3-12
36. Hellman P, Ladjevardi S, Skkogseid B et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26: 1052-1056
37. Berber E, Flesher N, Siperstein A. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. Worl J Surg 2002; 26: 985-990
38. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neureocendocrine liver metastases. World J Surg 2001; 25: 693-696